Amneal Scores Second US Biosimilar Approval With Avastin Rival

Alymsys Bevacizumab With mAbxience Is Second Of Three Expected Nods This Year

 
• By Dave Wallace

Amneal has received approval for its second US biosimilar in the form of the mAbxience-developed Alymsys rival to Avastin. The product represents just the third biosimilar version of bevacizumab to be approved in the US.

1 2 3 pool billiard balls
Amneal now has two biosimilar approvals and is lining up a third • Source: amana images inc. / Alamy Stock Photo

More from Biosimilars

More from Products